Oura's $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring

Oura launched its IPO roadshow targeting a Sept. 28 Nasdaq debut, offering 50 million shares at $40-$44 and seeking a $12.8 billion-$14.1 billion market capitalization. For the nine months through June 30, 2026, revenue rose 74% year over year to $1.21 billion, subscription revenue increased 121% to $240.5 million, gross margin expanded 400bps to 55%, and net income reached $60.8 million. Eli Lilly indicated interest in purchasing up to $100 million of shares and Dragoneer up to $300 million, supporting Oura's positioning as a biometric-data platform for metabolic healthcare. Risks include a 9.7x annualized-sales valuation, hardware comprising roughly 80% of revenue, substantial secondary selling, limited net primary capital after RSU tax obligations, and an active consumer class-action lawsuit over sleep-tracking claims.

Analysis

The key underwriting question is whether OURA deserves a healthcare-software multiple before its revenue mix proves it. At the indicated valuation, investors are paying roughly 10x run-rate sales for a business whose earnings sensitivity remains dominated by discretionary hardware demand; the subscription layer must both sustain hypergrowth and expand materially as a share of revenue to prevent a de-rating toward GRMN-like consumer-device comparables. The large secondary component also creates an unfavorable near-term technical setup: limited balance-sheet enhancement, meaningful sponsor liquidity, and likely lockup-overhang pressure once post-IPO demand normalizes.

LLY's participation is strategically useful but should not be capitalized as guaranteed enterprise revenue. The economically important proof point over the next 1-3 quarters is whether GLP-1-channel distribution produces paid-member additions, lower acquisition costs, or reimbursed clinical programs—not feature integration or partnership announcements. DXCM has the more direct second-order upside if combined glucose-and-recovery workflows improve Stelo engagement and sensor replenishment, though OURA could eventually become a data-aggregation layer that weakens device-specific customer ownership.

Near-term upside is concentrated in a scarcity/retail-driven IPO squeeze if pricing clears above range and the free float is constrained; that is a trading dynamic, not validation of durable unit economics. The contrarian risk is that high wear time measures utility but does not establish clinical accuracy, reimbursement eligibility, or pricing power. Any litigation-driven marketing revision, slowing subscription growth, or gross-margin retreat would expose the gap between the current valuation and the still hardware-heavy profit pool over the first 6-18 months.

Key Decisions for Investors

• Do not chase OURA in the opening week. Establish a watch level rather than a core long; revisit after the first earnings report if subscription growth remains above 100%, gross margin holds at or above 55%, and management quantifies GLP-1-channel conversion or CAC improvement. A post-lockup entry at a 20-30% discount to the IPO price would offer materially better asymmetry.
• For IPO-event exposure only, buy a small OURA position after stabilization rather than at the open, with a hard thesis stop if it closes below the IPO price for five consecutive sessions. Target a 20-30% upside from a constrained-float momentum phase; size for a full loss of the initial risk allocation given limited public trading history.
• Prefer DXCM over OURA for the metabolic-monitoring theme over 6-12 months: DXCM monetizes recurring consumables and may benefit from broader Stelo adoption without assuming OURA's valuation multiple. Reassess if integrated-user engagement fails to lift sensor utilization or if OTC CGM pricing compresses materially.
• Avoid treating LLY's indicated investment as a reason to add LLY. The financial exposure is immaterial; the relevant monitor is whether LillyDirect begins reporting measurable wearable-enabled adherence or persistence benefits, which could matter to LLY's long-duration GLP-1 economics.
• Monitor the first lockup-expiration schedule, secondary-sale disclosures, and the consumer-claims litigation. A material adverse ruling or guidance that subscription growth falls below 70% should trigger a short-bias review, particularly if OURA continues to trade above 9x forward sales.